Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:24 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 4,129 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Neck Neoplasms Clear all

Conditions: Cervical Cancer
Interventions: cisplatin, paclitaxel, brachytherapy, radiation therapy; Drug · Radiation
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 31
States / cities: Phoenix, Arizona • Newark, Delaware • Chicago, Illinois + 26 more

Conditions: Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Verrucous Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer
Interventions: bortezomib, irinotecan hydrochloride, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Thyroid Cancer
Interventions: Euthyroid Group; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 2
States / cities: Baltimore, Maryland • Houston, Texas

Conditions: Anaplastic Thyroid Cancer, Thyroid Cancer, BRAF Gene Mutation, BRAF Mutation-Related Tumors
Interventions: Dabrafenib, Trametinib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Esophageal Cancer
Interventions: VLE imaging for staging EAC; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 95 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Breast Carcinoma, Caregiver, Head and Neck Carcinoma, Lung Carcinoma, Prostate Carcinoma, Tobacco Use
Interventions: Communication Skills Training, Medical Chart Review, Questionnaire Administration, Tobacco Cessation Counseling; Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: Not listed
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Esophageal Neoplasms, Lung Neoplasms, Mesothelioma, Thymus Neoplasms, Neoplasms, Germ Cell and Embryonal
Interventions: Mithramycin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Major Salivary Gland Carcinoma, Minor Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage IV Major Salivary Gland Carcinoma, Stage IVA Major Salivary Gland Carcinoma, Stage IVB Major Salivary Gland Carcinoma, Stage IVC Major Salivary Gland Carcinoma
Interventions: Ipilimumab, Laboratory Biomarker Analysis, Nivolumab; Biological · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cervical Cancer, Human Papillomavirus Infection
Interventions: Telephone Recall, Mailed HPV Self-Sampling Kit, Patient Navigation; Behavioral
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 30 Years to 65 Years · Female only
Enrollment: 111 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cervical Cancer, Cervical Cancer Recurrent, Cervical Cancer Metastatic
Interventions: Stereotactic body radiation therapy (SBRT), Atezolizumab; Radiation · Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 2
States / cities: Tampa, Florida • Hilliard, Ohio

Conditions: Cervix Carcinoma
Interventions: Proflavine, High-Resolution Microendoscopy (HRME) Imaging; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 21 Years to 64 Years · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Intensity modulated radiation therapy (IMRT); Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Cervical Cancer
Interventions: Ultraviolet Microscopic Analysis; Diagnostic Test
Lead sponsor: University of Arizona; Other
Eligibility: 21 Years and older · Female only
Enrollment: 232 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Head and Neck Cancer
Interventions: STAT 3 DECOY; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: HNSCC, ESCC, Esophageal Adenocarcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Ovarian Cancer, NSCLC, Cervical Cancer, Endometrial Cancer, Triple Negative Breast Cancer (TNBC)
Interventions: NRM-823; Drug
Lead sponsor: Normunity AccelCo, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 18
States / cities: Denver, Colorado • New Haven, Connecticut • Washington D.C., District of Columbia + 13 more

Conditions: Blood Pressure, Hypertension, Cancer, Cancer, Breast, Cancer of Prostate, Cancer Colorectal, Cancer, Endometrial, Cancer of Head and Neck, Non Small Cell Lung Cancer, CVD - Cardiovascular Disease, Diabetes Mellitus, Hypercholesterolemia, Diabetes, Cancer of Esophagus, Cancer of Liver, Cancer, Renal Cell, Cancer of Pancreas, Cancer Ovaries
Interventions: iGuide Intervention (Self-guided), iGuide 2 Intervention (Tailored/Targeted), Control; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 79 Years
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN
Interventions: MEDI4736, MEDI4736 + Tremelimumab, Standard of Care; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 96 Years
Enrollment: 736 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 23
States / cities: Tucson, Arizona • Fullerton, California • Los Angeles, California + 18 more

Conditions: Thyroid Cancer, Thyroid Nodule, Thyroid Neoplasms, Thyroid Goitre, Thyroid Diseases, Parathyroid Diseases, Parathyroid Adenoma, Parathyroid Hyperplasia
Interventions: Acetaminophen 500Mg Cap, Tylenol #3 Oral Tablet, Tramadol; Drug
Lead sponsor: Minerva A Romero Arenas; Other
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Edinburg, Texas

Conditions: Head and Neck Neoplasms, Lung Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms
Interventions: [F-18]-5-FLUORO-2'-DEOXYCYTIDINE, Tetrahydrouridine intravenous (IV), Tetrahydrouridine (oral), Positron emission tomography (PET)/Computed tomography (CT); Drug · Diagnostic Test
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cancer of Head and Neck, Smoking
Interventions: Not listed
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years to 35 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2004
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: NSCLC, HNSCC, Melanoma, Metastatic Cancer, Advanced Solid Tumor, Advanced Cancer
Interventions: CJRB-101, Pembrolizumab injection; Drug
Lead sponsor: CJ Bioscience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Irvine, California • Pittsburgh, Pennsylvania

Conditions: Neoplasms, Head and Neck
Interventions: feladilimab, Pembrolizumab, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 13
States / cities: Duarte, California • Washington D.C., District of Columbia • St. Petersburg, Florida + 10 more

Conditions: Cervical Cancer Screening, HIV Infections
Interventions: Not listed
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, Cervical Cancer
Interventions: Kin KeeperSM Cancer Prevention Intervention, Standard of care; Behavioral · Other
Lead sponsor: Michigan State University; Other
Eligibility: 21 Years to 70 Years · Female only
Enrollment: 516 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: East Lansing, Michigan

Search by objective public record fields.

Radiation Therapy Plus Paclitaxel and Cisplatin in Treating Patients With Cervical Cancer

Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer

Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer

Staging of Superficial EAC Using VLE

Provider Training in Increasing Patient Tobacco Cessation Counseling and Referrals for Patients With Cancer Undergoing Radiation Therapy

Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases

Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer

Prospective Evaluation of Self-Testing to Increase Screening (PRESTIS) Asian/Asian American Women Supplement

SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer

Use of High-Resolution Microendoscopy (HRME) in Patients With Adenocarcinoma In-Situ (AIS) of the Cervix

INRT-AIR: A Prospective Phase II Study of Involved Nodal Radiation Therapy

Point-of-Care Ultraviolet Microscopy for Cervical Cancer Screening

STAT3 DECOY in Head and Neck Cancer

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

Onco-primary Care Networking to Support TEAM-based Care

Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer

Minimizing Narcotic Analgesics After Endocrine Surgery

Imaging Study for FdCyd and THU Cancer Treatment

Assessment of Early Genetic Changes in Smokers

Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer

Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Anal HPV Infection and Abnormal Cytology in HIV-infected Women

Kin KeeperSM: Reducing Disparities Through Cancer Literacy and Screening